Form 4: BioMarin Director Timothy Walbert Receives Stock Grant

Director Timothy P. Walbert acquired 7,490 restricted stock units in BioMarin Pharmaceutical Inc. as part of a standard equity grant.

Summary

• Director Timothy P. Walbert was granted 7,490 restricted stock units (RSUs) on June 2, 2026.
• The transaction resulted in a direct beneficial ownership of 17,270 shares of BioMarin common stock.
• The reporting person maintains an additional indirect interest of 416 shares held by Prairie Capital Ventures LLC.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine administrative filing regarding director compensation.

Positives

• The grant of equity to a director aligns personal interests with long-term shareholder value.

Negatives

• None identified.

Risks

• None identified.

Future Outlook

Not applicable as this is a routine disclosure of director equity compensation.

Industry Context

StockSavvy.ai notes that director equity grants are standard corporate governance practices in the biotechnology sector to ensure board members have a vested interest in company performance.

Comparison to Industry Standards

• The grant is consistent with standard compensation packages for independent directors at mid-to-large cap pharmaceutical companies.

Stakeholder Impact

• Minimal impact on shareholders as this is a standard equity incentive grant.

Next Steps

• No further actions required by the reporting person regarding this specific transaction.

Key Dates

Keywords

BioMarin, BMRN, Insider Trading, Form 4, Equity Grant, Director Compensation